Patient Safety Authority Logo

Skip navigation links
HOME
PATIENT SAFETY AUTHORITYExpand PATIENT SAFETY AUTHORITY
PA-PSRS and PASSKEYExpand PA-PSRS and PASSKEY
PATIENT SAFETY ADVISORIESExpand PATIENT SAFETY ADVISORIES
PATIENTS AND CONSUMERSExpand PATIENTS AND CONSUMERS
NEWS AND INFORMATIONExpand NEWS AND INFORMATION
EDUCATIONAL TOOLSExpand EDUCATIONAL TOOLS
AUTHORITY EVENTSExpand AUTHORITY EVENTS







ADDRESS:
Patient Safety Authority
333 Market Street
Lobby Level
Harrisburg, PA 17120


Phone: 717-346-0469
Fax: 717-346-1090


  
Advisory Banner
Foiled Again! Risk from Transdermal Patches in
MRI Procedures
PA PSRS Patient Saf Advis 2006 Sep;3(3):18. 
 

In a recently submitted PA-PSRS report, a patient underwent an MRI while wearing a transdermal medication patch. Though this patient apparently suffered only minor skin irritation directly beneath the patch, a less healthy patient with impaired skin integrity could have sustained a significant burn from this type of event. While this is the first MRI safety report received by PA-PSRS related to transdermal patches, healthcare workers have reported patient injuries in similar cases to other patient safety organizations for several years.

MRI systems generate radiofrequency (RF) pulses that create the magnetic resonance signal used in imaging. If electrically conductive materials are introduced within the bore of the MR system, the RF pulses produce electrical currents that can excessively heat the conductor and burn tissue.1,2

Transdermal patches have three basic components: a liner that is peeled away before application, the drug, and the backing.3 Some patches have an aluminized or foil backing in the layer furthest from the skin. This layer contains the drug and allows it to slowly disperse through the skin, but aluminized backings also serve as electrical conductors.4 The dangers of ferromagnetic materials near MRI systems are well documented.5 Though transdermal patches are not ferromagnetic, they can result in burns during an MRI procedure.6

Healthcare workers can reduce the risk of this problem by:

  • Including in a pre-MRI screening checklist a question asking patients whether they use a patch for administering any drug such as nitroglycerin or for smoking cessation.4,7 Having patients remove any patches before undergoing MRI and replacing them with a new patch after the MRI is completed.3,7 Reusing the removed patch is not advised because the patch may have lost its adhesiveness or the drug may leak once the patch is exposed to the air for an extended period.4
  • Posting a warning/list of specific patient items/implants that prohibit the use of MRI, including aluminized/foil-backed medication patches. This can be a helpful reference for both healthcare workers and patients.4,8
  • Providing physician offices, patient care departments, and patients with a brochure concerning MRI hazards and contraindications.8,9
  • Contacting the patch prescriber, if necessary, to determine whether the drug delivery system can be interrupted for the time required to conduct the MRI.4
  • Educating those responsible for prescribing, medication administration, screening, transporting, and performing the MRI about the hazards involved with this procedure.6
  • Prior to conducting an MRI, reviewing the medication patch drug package insert to identify whether wearing the patch during MRI is contraindicated.

Notes

  1. Institute for Safe Medication Practices. Burns in MRI patients wearing transdermal patches. ISMP Medication Safety Alert! 2004 Apr 8;9(7):1.
  2. ECRI. Safety concerns in the MR environment. Healthcare Risk Control Risk Analysis. 2006 Mar;4(5):1-28.
  3. Schulmeister L. Transdermal patches: medicine with muscle. Nursing 2005 Jan;35(1):48-52.
  4. Karch AM. Practice errors: don’t get burnt by the MRI: transdermal patches can be a hazard to patients. AJN 2004 Aug;104(8):31.
  5. Pennsylvania Patient Safety Reporting System. MRI hidden risks. Patient Safety Week Advisory. 2004 Mar;1(1):3.
  6. Health Canada. Health Products and Food Branch Inspectorate. Association of transdermal drug patches with thermal burns during magnetic resonance imaging procedures [notice to hospitals online.] 2005 Apr 26 [cited 2006 Apr 27]. Available from Internet: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/
    prof/_2005/mri-irm_patch-timbre_nth-ah-eng.php    .
  7. Shellock FG. Screening patients for MR procedures and individuals for the MR environment [online.] 2002 [cited 2005 Dec 15]. Available from Internet: http://www.MRIsafety.com/SCREENING_FORM/PreScrnF.pdf.
  8. NE Wisconsin MRI Center. MR safety [online.] [cited 2006 Apr 25]. Available from Internet: http://www.newmri.com/html/mr_safety.asp.
  9. Healthtouch Online for Better Health. Magnetic resonance imaging [online.] 2006 [cited 2006 Apr 27]. Available from Internet:
    http://www.healthtouch.com/bin/EContent_HT/cnoteShowLfts.asp?
    fname=02601&title=magnetic+resonance+imaging+&cid=hthlth
Following are examples of patches that may have aluminized backings.1,4 If in doubt, it’s best to advise the patient to remove the patch prior to the MRI and to apply a new patch after the MRI is completed. Contact the patch prescriber to determine whether the drug delivery system can be interrupted during the MRI procedure.

  • Androderm (testosterone)
  • Catapres-TTS (clonidine)
  • Deponit (nitroglycerine)
  • Habitrol (nicotine)
  • Nicoderm (nicotine)
  • Nicotrol (nicotine)
  • Transderm-nitro (nitroglycerin)
  • Transderm-scop (scopolamine)
 
 Browse by Topic
go button Discipline
go button Audience
go button Care Setting
go button Event
go button Patient Safety Focus
go button Hospital-Acquired Condition
Print Page Print / Save PDF
Email to a Friend Email to a Friend
Editorial Information Editorial Information
Subscribe to Advisory Subscribe to the Advisories
Navigation  
Back to Advisory Issue

Article Sections
Foiled Again! Risk from Transdermal Patches in MRI Procedures
Notes

Supplemental Material
Examples



THE PENNSYLVANIA PATIENT SAFETY AUTHORITY AND ITS CONTRACTORS  
PSA LOGO The Pennsylvania Patient Safety Authority is an independent state agency created by Act 13 of 2002, the Medical Care Availability and Reduction of Error (“Mcare”) Act. Consistent with Act 13, ECRI Institute, as contractor for the Authority, is issuing this publication to advise medical facilities of immediate changes that can be instituted to reduce Serious Events and Incidents. For more information about the Pennsylvania Patient Safety Authority, see the Authority’s Web site at www.patientsafetyauthority.org .      
ECRI LOGO ECRI Institute, a nonprofit organization, dedicates itself to bringing the discipline of applied scientific research in healthcare to uncover the best approaches to improving patient care. As pioneers in this science for more than 40 years, ECRI Institute marries experience and independence with the objectivity of evidence-based research. More than 5,000 healthcare organizations worldwide rely on ECRI Institute’s expertise in patient safety improvement, risk and quality management, and healthcare processes, devices, procedures and drug technology.      

ISMP Logo The Institute for Safe Medication Practices (ISMP) is an independent, nonprofit organization dedicated solely to medication error prevention and safe medication use. ISMP provides recommendations for the safe use of medications to the healthcare community including healthcare professionals, government agencies, accrediting organizations, and consumers. ISMP’s efforts are built on a nonpunitive approach and systems-based solutions.      
 
©2012 Pennsylvania Patient Safety Authority                                                Home      Who We Are      Contact Us     Subscribe to Advisories and Press Releases   Site Map     Privacy Statement